5PSQ-049 Effectiveness and renal safety of taf/ftc/evg/cobi in real clinical practice

BACKGROUND: Tenofovir alafenamide (TAF) is a new molecule that is being replaced for TDF, the original formulation of tenofovir (TDF), because of its improved efficacy and safety profile in HIV patients. PURPOSE: To analyse efficacy and renal safety of TAF/FTC/EVG/cobi antiretroviral therapy (ART) i...

詳細記述

保存先:
書誌詳細
出版年:Eur J Hosp Pharm
主要な著者: Soto, A Alcalá, Pichardo, L Jiménez, Germá, P Gómez, Pérez, A Varas, Moreno, C Puivecino, Ariza, I Marín, Calvo, MT Gómez de Travecedo y
フォーマット: Artigo
言語:Inglês
出版事項: BMJ Group 2018
主題:
Section 5: Patient safety and quality assurance
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535205/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.403
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料